TSMC Accelerates 2nm Expansion as AI Chip Demand Surges 
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
China Consumer Stocks Near Decade Lows as AI Shares Surge 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Germany’s 2026 Growth Outlook Strengthens on Fiscal Spending 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
Trump, Xi Focus on Trade and AI at White House Summit 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens 
Fed Unveils Stablecoin Rules Under GENIUS Act 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
OpenAI AI Agents Bypassed UN Website Controls in Data Scraping 
Add as a preferred source on Google
Medtronic plc, a leading global healthcare technology company headquartered in Dublin, Ireland, is set to acquire EOFlow, a wearable insulin patch maker based in South Korea, for $738 million.
The Korea Economic Daily reported that Medtronic confirmed it has signed a share purchase agreement (SPA) to buy all the shares of EOFlow's chief executive officer Jesse Kim and president Luis Malave. The medical device company said that their shares are priced at KRW30,000 per share or about $22.60.
The price is said to be higher 19.8% higher compared to the KRW25,050 closing stock price on Friday, May 26. This is also said to be EOFlow's highest share price since November 2021, and the surge was hinted to be due to Medtronic's acquisition plan of the company.
EOFlow said that its CEO Jesse Kim currently owns the biggest stake in the company, and he signed a SPA with Medtronic Korea Holdings for the sale of the 18.58% stake, which he owns for KRW169.2 billion. On the other hand, EOFlow's president Luis Malave holds less than five percent of the company.
"Our goal is to simplify diabetes management and deliver the well-established benefits of automated insulin delivery to our customers in the ways they want and need," Medtronic Diabetes' executive vice president and president, Que Dallara, said in a press release. "We are excited to introduce a differentiated wearable patch option to provide more patient choice and drive further innovation for those who want to use technology to make living with diabetes easier."
EOFlow's founder and CEO, Jesse Kim, added, "We are thrilled to accelerate our next phase of growth with a partner like Medtronic who shares our goal of simplifying diabetes management to make life easier for the customers we serve."
Meanwhile, JP Morgan Securities LLC has been assigned by Medtronic as its financial advisor for the transaction, while Kim & Chang and Ropes & Gray LLP serve as its legal advisors. For EOFlow, it has hired Goldman Sachs & Co. LLC as its financial advisor and Bae, Kim & Lee LLC acting as its legal advisor.
Photo by Tony Webster/Flickr(CC BY 2.0)
